Kurt von Emster
Managing Partner
Abingworth
Kurt joined Abingworth in January 2015 and brings over 35 years of experience in life science investment in both private and public companies. He holds board positions at the Abingworth portfolio companies Iambic, Jasper, Orbus, Launch Therapeutics, SFJ Pharmaceuticals and Tizona Therapeutics. He is a member of the Abingworth / Carlyle BioVentures and Clinical Co-Development Investment Committees.
Kurt began his career as a Biotechnology and Healthcare Analyst and Portfolio Manager at Franklin Templeton. He then became a General Partner at MPM Capital. In 2009, he co-founded venBio, a US healthcare investment firm and most recently was a Partner in the San Francisco office. Kurt holds a Bachelor of Arts in Business and Economics and is a CFA. He is based in Menlo Park California.
Sessions
-
22-Jun-202626ABInvestment, Innovation, and the Business Risk of Policy
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}